Navigation Links
Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
Date:8/11/2008

CAMBRIDGE, Mass., Aug. 11 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. today announced that the first patient has received an initial dose in a Phase 1 clinical study of the Company's first oncology product, MM-121, a fully human monoclonal antibody and a first-in-class therapeutic designed to block signaling of the ErbB3 receptor.

ErbB3 is a receptor in the ErbB family, a pathway that plays a critical role in cancer signaling. With the initiation of the Phase 1 trial, MM-121 becomes the first systems biology product as well as the first selective ErbB3 antagonist to enter human clinical development.

"We used a combination of high-throughput biology and computer simulation to discern the importance of targeting ErbB3 signaling in tumor cells," said Dr. Ulrik B. Nielsen, Senior Vice President of Research. "We believe this is the first systems-designed therapeutic in clinical development. Until now, computer simulation has not been widely applied toward understanding optimal therapeutic strategies for treating cancers driven by complex signaling pathways."

Preclinical data demonstrating the impact of MM-121 in multiple cancer models were presented at the annual meeting of the American Association for Cancer Research in April. The Phase 1 dose escalation study will evaluate the safety and pharmacokinetics (PK) of MM-121. Enrollment is underway at Fox Chase Cancer Center and two additional leading oncology sites are expected to participate in the trial later this year.

"ErbB3 is now recognized as a potentially important target in many types of cancer including lung, breast, colorectal, ovarian and others," said Dr. William J. Slichenmyer, Senior Vice President and Chief Medical Officer at Merrimack. "Preclinical studies of MM-121 have demonstrated antitumor activity in a wide range of tumor types and a very favorable safety profile. We are optimistic that these findings may translate into clinical benefit for patients who participate in the clinical trials. In addition, we are very pleased to be working with leading clinical investigators at outstanding academic cancer research centers."

Merrimack has developed a broad intellectual property position around its oncology therapeutic portfolio, including MM121. This portfolio includes U.S. and international patent filings relating to compositions of matter and methods of use as well as licensed patents and pending patent applications, trade secrets and proprietary know-how.

About MM-121

MM-121 is a monoclonal antibody designed to block signaling of the ErbB3 receptor, a receptor in the ErbB family, a pathway that plays a critical role in cancer signaling. Upon initiation of the Phase 1 trial, MM-121 becomes the first systems biology product as well as the first selective ErbB3 antagonist to enter human clinical development. Preclinical data exhibiting MM-121's impact on multiple cancer models (including lung, ovarian, breast, prostate and renal) were presented at the annual meeting of the American Association for Cancer Research in April 2008. The Phase 1 trial is being conducted at 3 centers in the United States.

About Merrimack

Merrimack Pharmaceuticals, Inc., is a biotechnology company focused on the discovery, design and development of novel treatments for diseases in the areas of autoimmunity and cancer. Its autoimmune candidate, MM-093, is currently in Phase 2 clinical development. Its first oncology product, MM-121 is currently in Phase 1 clinical development. MM-093 and MM-121 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The company's proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, enables the high throughput profiling of protein networks as a basis for improved validation, lead identification and speed in the development of innovative therapeutics. Merrimack is a privately-held company based in Cambridge, Massachusetts. For additional information, please visit http://www.merrimackpharma.com.

Contact: Kathleen Petrozzelli, Senior Manager, Corporate Communications, 617-441-1043


'/>"/>
SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
2. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... The ... context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The ... transformative for performing systematic gain-of-function studies. , This complement to loss-of-function studies, ...
(Date:10/11/2017)... ... 2017 , ... Proscia Inc ., a data solutions ... “Pathology is going digital. Is your lab ready?” with Dr. Nicolas Cacciabeve, Managing ... how Proscia improves lab economics and realizes an increase in diagnostic confidence.* ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are ... 5.5 million people each year. Especially those living in larger cities are affected by ... in one of the most pollution-affected countries globally - decided to take action. , ...
(Date:10/10/2017)... DIEGO, CALIF. (PRWEB) , ... October 10, 2017 , ... ... as part of its corporate rebranding initiative announced today. The bold new look ... its reach, as the company moves into a significant growth period. , It will ...
Breaking Biology Technology:
(Date:4/19/2017)... , April 19, 2017 ... its vendor landscape is marked by the presence of ... is however held by five major players - 3M ... these companies accounted for nearly 61% of the global ... leading companies in the global military biometrics market boast ...
(Date:4/13/2017)... MONICA, Calif. , April 13, 2017 ... New York will feature emerging and evolving ... Summits. Both Innovation Summits will run alongside the expo ... of speaker sessions, panels and demonstrations focused on trending ... coast,s largest advanced design and manufacturing event will take ...
(Date:4/11/2017)... 2017 Research and Markets has announced the ... to their offering. ... eye tracking market to grow at a CAGR of 30.37% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
Breaking Biology News(10 mins):